Loss of ATM positively regulates the expression of hypoxia inducible factor 1 (HIF-1) through oxidative stress: Role in the physiopathology of the disease

Cell Cycle

Volumn 9, Issue 14, 2010, Pages 2886-2894

  Ousset, Marielle ^a,b   Bouquet, Fanny ^a,b,e   Fallone, Frédérique ^a,b   Biard, Denis ^d   Dray, Cedric ^a,c   Valet, Philippe ^a,c   Salles, Bernard ^a,b   Muller, Catherine ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^c INSERM   (France)

^d DIF   (France)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Ataxia telangiectasia; Hypoxia; Hypoxia inducible factor 1 (HIF 1); Insulin resistance; Oxidative stress; Telangiectasia

Indexed keywords

ATM PROTEIN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CELL METABOLISM; DIABETES MELLITUS; DOWN REGULATION; GLUCOSE INTOLERANCE; HUMAN; HUMAN CELL; HYPOXIA; INSULIN RESISTANCE; IONIZING RADIATION; NERVE CELL DEGENERATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ATAXIA TELANGIECTASIA;

EID: 77956867103     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.14.12253     Document Type: Article

References (40)

1. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004; 3:1187-96.
2. Shiloh Y. ATM: ready, set, go. Cell Cycle 2003; 2:116-7.
3. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
4. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst) 2002; 1:3-25.
5. Bar RS, Levis WR, Rechler MM, Harrison LC, Siebert C, Podskalny J, et al. Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N Engl J Med 1978; 298:1164-71.
6. Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med 1970; 282:1396-402.
7. Blevins LS Jr, Gebhart SS. Insulin-resistant diabetes mellitus in a black woman with ataxia-telangiectasia. South Med J 1996; 89:619-21.
8. Jacobson BS. Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement. Am J Pathol 2000; 156:737-42.
9. Becker Y. Cancer in ataxia-telangiectasia patients: analysis of factors leading to radiation - induced and spontaneous tumors. Anticancer Res 1986; 6:1021-32.
10. Kamiya M, Yamanouchi H, Yoshida T, Arai H, Yokoo H, Sasaki A, et al. Ataxia telangiectasia with vascular abnormalities in the brain parenchyma: report of an autopsy case and literature review. Pathol Int 2001; 51:271-6.
11. Cuatrecasas M, Santamaria G, Velasco M, Camacho E, Hernandez L, Sanchez M, et al. ATM gene expression is associated with differentiation and angiogenesis in infiltrating breast carcinomas. Histol Histopathol 2006; 21:149-56.
12. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5:343-54.
13. Michieli P. Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle 2009; 8:3291-6.
14. Brahimi-Horn MC, Pouyssegur J. HIF at a glance. J Cell Sci 2009; 122:1055-7.
15. Dery MA, Michaud MD, Richard DE. Hypoxiainducible factor 1: regulation by hypoxic and nonhypoxic activators. Int J Biochem Cell Biol 2005; 37:535-40.
16. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. Faseb J 2003; 17:271-3.
17. Angele S, Lauge A, Fernet M, Moullan N, Beauvais P, Couturier J, et al. Phenotypic cellular characterization of an ataxia telangiectasia patient carrying a causal homozygous missense mutation. Hum Mutat 2003; 21:169-70.
18. Kietzmann T, Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 2005; 16:474-86.
19. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9:759-69.
20. Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2000; 2:893-8.
21. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994; 219:713-25.
22. Hansen PA, Wang W, Marshall BA, Holloszy JO, Mueckler M. Dissociation of GLUT4 translocation and insulin-stimulated glucose transport in transgenic mice overexpressing GLUT1 in skeletal muscle. J Biol Chem 1998; 273:18173-9.
23. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 2001; 15:2520-32.
24. Bott L, Thumerelle C, Cuvellier JC, Deschildre A, Vallee L, Sardet A. Ataxia-telangiectasia: a review. Arch Pediatr 2006; 13:293-8.
25. Rezvani HR, Dedieu S, North S, Belloc F, Rossignol R, Letellier T, et al. Hypoxia-inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem 2007; 282:16413-22.
26. Prokopcova J, Kleibl Z, Banwell CM, Pohlreich P. The role of ATM in breast cancer development. Breast Cancer Res Treat 2007; 104:121-8.
27. Ye C, Cai Q, Dai Q, Shu XO, Shin A, Gao YT, et al. Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival. Cancer 2007; 109:1729-35.
28. Yan M, Rayoo M, Takano EA, Fox SB. BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br J Cancer 2009; 101:1168-74.
29. Sanjuan-Pla A, Cervera AM, Apostolova N, Garcia-Bou R, Victor VM, Murphy MP, et al. A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha. FEBS Lett 2005; 579:2669-74.
30. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, et al. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004; 118:781-94.
31. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 2002; 277:48403-9.
32. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1alpha. Mol Cell Biol 2004; 24:5223-34.
33. Watters D, Kedar P, Spring K, Bjorkman J, Chen P, Gatei M, et al. Localization of a portion of extranuclear ATM to peroxisomes. J Biol Chem 1999; 274:34277-82.
34. Vert JP, Foveau N, Lajaunie C, Vandenbrouck Y. An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 2006; 7:520.
35. Biard DS. Untangling the relationships between DNA repair pathways by silencing more than 20 DNA repair genes in human stable clones. Nucleic Acids Res 2007; 35:3535-50.
36. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11:72-82.
37. Muller C, Monferran S, Gamp AC, Calsou P, Salles B. Inhibition of Ku heterodimer DNA end binding activity during granulocytic differentiation of human promyelocytic cell lines. Oncogene 2001; 20:4373-82.
38. Bouquet F, Muller C, Salles B. The loss of gamma-H2AX signal is a marker of DNA double strand breaks repair only at low levels of DNA damage. Cell Cycle 2006; 5:1116-22.
39. Carpene C, Daviaud D, Boucher J, Bour S, Visentin V, Gres S, et al. Short- and long-term insulin-like effects of monoamine oxidases and semicarbazide-sensitive amine oxidase substrates in cultured adipocytes. Metabolism 2006; 55:1397-405.
40. Li L, Tao J, Davaille J, Feral C, Mallat A, Rieusset J, et al. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 2001; 276:38152-8.